Oxford Biomedica plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OXBDF | ONT.L | RGNX | FDMT | 688238.SS | AVIR | |
|---|---|---|---|---|---|---|
| Market cap | 875.72M | 2.06B | 508.96M | 678.40M | 4.36B | 357.71M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -29.1 | -2.6 | -3.0 | — | -3.0 |
| Price/book | 11.2 | 4.8 | 5.8 | 1.7 | 3.3 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −17.13% | +59.62% | −30.98% | +12.45% | −14.27% | +37.23% |
| Today | 0.00% | 0.00% | +1.05% | +2.76% | +5.49% | +6.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All OXBDF news ›FTSE 100 Outsider Oxford Biomedica (LSE:OXB) in Focus
This week's sector commentary on regulatory wins and a positive tone toward British healthcare has widened the circle of names being discussed, and smaller specialists have benefited from that attention. Analysts who follow the group…
Oxford BioMedica (OTCMKTS:OXBDF) Sees Large Volume Increase – Should You Buy?
Posted by Michael Walen on Nov 2nd, 2026 Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares saw unusually-strong trading volume on Monday. Approximately 26,442 shares changed hands during mid-day trading, an increase of 373% from…
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Oxford BioMedica (OXBDF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Oxford BioMedica (OXBDF) with bullish sentiments. In a report released today, Phil Nadeau from TD Cowen…
REG - Oxford Biomedica PLC - Appointment of Independent Non-Executive Director
Oxford, UK – 16 October 2026: OXB OXB, a global quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Dr Joachim Kreuzburg as an Independent Non-Executive Director, effective on 23 November 2026. Save as…
Whitbread raised; Segro, Oxford BioMedica cut
Published on 08/18/2026 at 04:39 am EDT Bernstein raises Whitbread to 'market-perform' (underperform) - price target 2,400 (2,100) pence Berenberg cuts Segro to 'hold' (buy) - price target 991 (995) pence DZ Bank raises fair value for…
Is Oxford Biomedica (LSE:OXB) Gaining Attention As Its Vector Platform Broadens In October?
It is one of the more specialised names on the London market, and its fortunes depend heavily on the progress of its clients' therapies through the clinic. The group built its name on LentiVector technology, and is now pushing its InAAVate…
Oxford Biomedica (LSE:OXB) Revenue Growth and Firm Guidance Support Recovery While FTSE 100 Trades Higher
Oxford Biomedica, a cell and gene therapy contract development and manufacturing organisation, reported growth in first-half revenue and maintained its full-year guidance. Manufacturing revenue rose on higher batch volumes, and a new…
Outside the FTSE 100, what does the latest incentive award say about Oxford Biomedica (LSE:OXB) as it builds its cell and gene therapy services?
Under the scheme described, performance is measured mainly through revenue and operating profitability, with revenue given the heavier weighting and margin the remainder, all assessed on a constant currency basis. Remuneration structures…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- kalkinemedia.com3
- theglobeandmail.com2
- marketscreener.com1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.